Interim Report Q3 2026
Interim Report Q1 2026
Interim Report Q2 2026
Interim Report Q3 2026
Annual Report 2025
Interim Report Q1 2025
Interim Report Q2 2025
Interim Report Q3 2025
Year-end Report Q4 2025
Annual Report 2024
Interim report Q1 2024
Interim report Q2 2024
Interim report Q3 2024
Year-end Report Q4 2024
Annual Report 2023
Interim report Q1 2023
Interim report Q2 2023
Interim report Q3 2023
Year-end report Q4 2023
Annual Report 2022
Interim report Q1 2022
Interim report Q2 2022
Interim report Q3 2022
Year-end Report Q4 2022
Annual Report 2021
Delårsrapport Q1 2021
Delårsrapport Q2 2021
Delårsrapport Q3 2021
Year-end report Q4 2021
Årsredovisning 2020
Older reports
2026
2025
2024
2023
2022
2021
2020
Summary
Comments by the CEO
Group development
Group development
Development in the quarter and the period
Financial position and cash flow
Employees
Acquisitions
Business areas
Business areas
Development Labtech
Development Medtech
Financial information by business area
Quarterly data
Net sales and EBITA
Financial information
Financial information
Group summary
Consolidated income statement
Consolidated statement of comprehensive income
Consolidated Balance sheet
Consolidated Statement of change in group equity
Consolidated cash flow statement
Key figures
Parent Company summary
Parent Company income statement
Parent Company balance sheet
Other information
Accounting policies
Risks and uncertainties
Transactions with related parties
Financial instruments
Pledged assets and contingent liabilities
Nomination Committee
Significant events after the end of the interim period
Affirmation
Auditor’s report
Definitions
Alternative performance measures
The share
Video conference
Financial calendar
Interim Report Q3 2026
/
Financial information
/
Other information
/
Affirmation
Stockholm, October 21, 2026
Fredrik Dalborg
President and CEO
previous
Significant events after the end of the interim period
next
Definitions
Loading...
